Benjamin L. Schlechter, MD

Medical Oncology

MAKE AN APPOINTMENT

Contact Information

Office Phone Number

857-215-0430

Appointments

617-632-5929

Biography

Benjamin L. Schlechter, MD

Dr. Schlechter is Senior Physician in the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute with a particular focus on colorectal cancer, anal cancer, and innovative immunotherapies. He previously worked in the laboratory of Dr. Carol L. Rosenberg at Boston University School of Medicine and Dr. Donald E. Ingber at the Wyss Institute at Harvard University. Dr. Schlechter is a former member of the faculty of Beth Israel Deaconess Medical Center as well as the former Director of Inpatient Hematology and Oncology there. He is an active participant in investigator-initiated, cooperative group, and industry funded clinical trials in GI malignancies. He currently focuses on the development of novel approaches to immunotherapy in GI cancers generally and colorectal cancer in particular. He is the Harvard-wide principal investigator of several cellular therapy trials for GI cancers as well as trials involving checkpoint inhibitors and novel chemotherapies.

Researcher

Physician

Senior Physician

Instructor in Medicine, Harvard Medical School

Centers/Programs

Gastrointestinal Cancer

Board Certification

Internal Medicine, 2011
Medical Oncology, 2014

Fellowship

Beth Israel Deaconess Medical Center

Residency

Beth Israel Deaconess Medical Center

Medical School

Tel Aviv University

Research

View Dr. Schlechter’s Research

My research interests focus on clinical innovations for patients with gastrointestinal malignancies. I am the Harvard-wide principal investigator for the PANOVA-3 clinical trial studying tumor treating fields in locally advanced pancreatic cancer; NUC-3373, a novel fluorouracil-like drug for colorectal cancer; and the ECOG EA2165 study of nivolumab after chemoradiotherapy for anal squamous cancer. I am on the Data Safety Monitoring Committees of PEN221 for advanced neuroendocrine tumors as well as AbGen107 for advanced gastrointestinal malignancies. I also have enrolled patients in multiple phase I, II, and III clinical trials for gastrointestinal malignancies. I was a lead enroller in the CATIQ phase II trial of isoquercetin to inhibit protein disulfide isomerase to prevent malignancy associated thrombosis in ambulatory cancer patients and have been an active participant in a study of fixed-dose versus weight- based enoxaparin as thromboprophylaxis for hospitalized cancer patients. In the past, I worked as a bench researcher in carcinogenesis in the laboratory of Carol Rosenberg at Boston University Medical Center and at the Wyss Institute for Biologically Inspired Engineering under the direction of Donald Ingber at HMS.

Support my research